Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease

Gabriel Velez1–3, Peter H. Tang1,2,4, Thiago Cabral5–7, Galaxy Y. Cho8–10, Daniel A. Machlab1,2, Stephen H. Tsang9–11, Alexander G. Bassuk12, and Vinit B. Mahajan1,2,4

1 Omics Laboratory, Stanford University, Palo Alto, CA, USA
2 Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA, USA
3 Medical Scientist Training Program, University of Iowa, Iowa City, IA, USA
4 Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
5 Department of Specialized Medicine, CCS, Federal University of Espirito Santo (UFES), Vitória, Brazil
6 Vision Center Unit, Ophthalmology, EBSEHR, HUCAM-UFES, Vitória, Brazil
7 Department of Ophthalmology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
8 Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, CT, USA
9 Barbara and Donald Jonas Laboratory of Stem Cells and Regenerative Medicine and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia University, New York, NY, USA
10 Department of Ophthalmology, Columbia University, New York, NY, USA
11 Department of Pathology & Cell Biology, College of Physicians & Surgeons, Columbia University, New York, NY, USA
12 Department of Pediatrics, University of Iowa, Iowa City, IA, USA

Correspondence: Vinit B. Mahajan, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, CA 94304, USA. e-mail: vinit.mahajan@stanford.edu

Received: 30 May 2018
Accepted: 30 July 2018
Published: XX September 2018

Keywords: personalized proteomics; biomarker; retina; vitreous; drug repositioning; diagnostics


Copyright 2018 The Authors

Proteomic analysis is an attractive and powerful tool for characterizing the molecular profiles of diseased tissues, such as the vitreous. The complexity of data available for analysis ranges from single (e.g., enzyme-linked immunosorbent assay [ELISA]) to thousands (e.g., mass spectrometry) of proteins, and unlike genomic analysis, which is limited to denoting risk, proteomic methods take snapshots of a diseased vitreous to evaluate ongoing molecular processes in real time. The proteome of diseased ocular tissues was recently characterized, uncovering numerous biomarkers for vitreoretinal diseases and identifying protein targets for approved drugs, allowing for drug repositioning. These biomarkers merit more attention regarding their therapeutic potential and prospective validation, as well as their value as reproducible, sensitive, and specific diagnostic markers.

Translational Relevance: Personalized proteomics offers many advantages over alternative precision-health platforms for the diagnosis and treatment of vitreoretinal diseases, including identification of molecular constituents in the diseased tissue that can be targeted by available drugs.

Background—The Precision Health Era

Precision Health aims to tailor medical therapies to each individual patient by taking into account his or her specific genetics, environments, and lifestyle choices. Recently empowered by large sets of molecular and clinical data and high-powered analytics, this concept is changing the field of healthcare, such that we now can customize therapies for each patient. No longer is medical practice confined exclusively to physicians, as basic scientists, engineers, entrepreneurs, healthcare providers, and patients all work together to bring innovative therapies from the laboratory bench to the bedside. Advances in our understanding of the molecular basis of disease are leading to the development of more timely interven-
of proteins, metabolites, and modifications within a disease. Proteomics refers to the large-scale detection and treating numerous complex ophthalmic diseases. Proteomics is a promising Precision Health strategy for diagnosing nonsystemic diseases.8–10 Vitreous fluid, urine, cerebral spinal fluid) may be sampled the fluid compartment near the diseased tissue (e.g., just anterior to the retina (Fig. 1A). Its composition is estimated to be 90% water, with a density that varies depending on anatomic location (i.e., core, cortex, and base).13,14 These characteristics change with age (i.e., from high to low viscosity) and often can be affected by numerous vitreoretinal diseases.13 Damaged retinal cells can release proteins into the vitreous that may remain undetected due to the invasive nature of retinal biopsy procedures.12 Proteomic analysis of the adjacent vitreous may serve as way to indirectly biopsy the diseased retina and identify changes in its proteome.15–19

Previous proteomic analysis of human vitreous from nondiseased postmortem eyes revealed a diverse catalogue of intracellular and extracellular proteins, proteoglycans, and small molecules that originate inside and outside the eye.16 Therefore, changes in the molecular composition of the vitreous can be expected...
Table 1. Precision Medicine Platforms

<table>
<thead>
<tr>
<th>Capability</th>
<th>Genomics</th>
<th>Proteomics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WGS/WES</td>
<td>Microarray</td>
</tr>
<tr>
<td>Protein mutations</td>
<td>Potential</td>
<td>Potential</td>
</tr>
<tr>
<td>Post-translational modifications</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Expression levels</td>
<td>Inferred</td>
<td>Yes</td>
</tr>
<tr>
<td>Metabolites</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>No</td>
<td>Inferred</td>
</tr>
<tr>
<td>Therapeutic monitoring</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

WGS, whole genome sequencing; WES, whole exome sequencing; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MRM, multiple reaction monitoring; SRM, selective reaction monitoring.

Figure 1. Summary of liquid biopsy techniques for ophthalmic tissues: cross sectional image of the human eye. (A) The vitreous is an extracellular matrix that covers the retina, lens, and ciliary body. The vitreous core is biopsied using a 23-gauge needle (depicted) or vitreous cutter and contains native vitreous proteins, systemic protein biomarkers, and retinal biomarkers that can be sampled through proteomic analysis. (B) The aqueous humor, located in the anterior chamber of the eye, is produced by the ciliary body. A 25-gauge needle can be inserted into the anterior chamber at the limbus to sample the aqueous humor for proteomic analysis. Graphical illustrations by Alton Szeto and Vinit Mahajan. Permission to publish granted by original artist.
to reflect key pathologic changes during vitreoretinal disease that correlate to disease onset, progression, and response to therapy. Vitreous biopsies frequently are used in the clinical management and diagnosis of intravitreal inflammation, infection, and cancer. Proteomic analysis of these liquid biopsies expands their clinical use in the personalized management of patient care.

Vitreous biopsies can be obtained from living patients in several ways. The least complex method is fine needle aspiration (FNA), where a 23-gauge needle is inserted through the pars plana to manually aspirate small amounts of fluid from the vitreous cavity (Fig. 1A). We reported that needle biopsies are comparable to vitreous cutter biopsies. A prospective case series of patients undergoing this office-based aspiration demonstrated the method to be reproducible and safe with an average of 100 to 200 μL undiluted vitreous obtained in 88% of patients. Although this procedure can be done safely under local anesthesia in an outpatient setting, its main limitation often is an inadequate volume of sample for large-scale proteomic studies. A second method involves pars plana vitrectomy (PPV) under local or general anesthesia within the operating room. This technique uses a small, high-speed guillotine called a vitrector to chop and aspirate the vitreous. Although more invasive, PPV ensures adequate sample volume, lower incidence of hypotony, and potentially better sampling of insoluble proteins. Previous studies that compared paired samples from 23-gauge FNA and 23-gauge PPV found that both techniques were nearly equivalent with regard to protein concentration, with only minor discrepancies in the relative abundance of certain proteins (as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)). We anticipated that future studies will address the proteomic quality of samples obtained from small-gauge vitrectomy techniques (e.g., 25- and 27-gauge PPV and microincision vitrectomy), which may be safer and less invasive.

The aqueous humor (AH), produced by the nonpigmented ciliary body epithelium, contains a complex mixture of electrolytes, organic solutes, and proteins that provides nutrition to the avascular tissues of the anterior chamber (Fig. 1B). The balance between production and drainage of AH is important in maintaining intraocular pressure and the refractive properties of the eye. AH typically is sampled before surgical intervention for cataract and contains over 600 nonredundant proteins. Changes in the proteomic content of the aqueous humor have been identified in diseases affecting the anterior chamber, including glaucoma and pseudoxfolliation syndrome. Similarly, proteomic studies on AH fluid from patients with macular degeneration and diabetic retinopathy have shown that AH protein content also can be affected in vitreoretinal diseases. AH fluid can be biopsied in the operating room by inserting a 25-gauge needle into the peripheral cornea at the limbus (Fig. 1B). Using this method, small volumes of AH (up to 100 μL) can be aspirated. Despite limitations in sampling AH to characterize vitreoretinal diseases (especially since cytokine profiles of aqueous and vitreous differ significantly), sampling these tissues may be more beneficial in diseases where vitrectomy surgery is not indicated.

Proper care and handling of surgical specimens is critical to quality control for subsequent proteomic analysis. To ensure tissues are immediately cataloged, processed, and stored, we developed the mobile operating room lab interface (MORLI). The MORLI system has several key components: a mobile operating room cart with a flat, lab bench surface, a computer with secure access to a sample database, a barcode scanner, and drawers with lab supplies for specimen collection (e.g., pipettors, centrifuge, dissecting microscope, cryotubes, and a small liquid nitrogen dewar). The MORLI cart allows samples to be processed away from the surgical field. Liquid vitreous samples are collected (via FNA or PPV) and passed to the lab technician who spins down the sample using a microcentrifuge (16,000 × g for 5 minutes at 4°C; to remove cellular debris), transfers the sample to a barcoded cryotube, and flash-freezes it in liquid nitrogen. The corresponding sample barcode is entered into an electronic database for efficient sample logging and retrieval. This biorepository system streamlined our personalized proteomics pipeline for the study of ophthalmic diseases. A similar system could catalog surgical specimens from other tissues.

For ethical reasons, researchers and clinicians do not sample the vitreous of healthy, living patients. Vitrectomy surgery requires a pathologic state, even in noninflammatory conditions, such as idiopathic macular holes and epiretinal membranes. Thus, we derive our control samples from patients with isolated forms of posterior segment pathology, such as idiopathic macular holes (IMHs), which are small, full-thickness retinal disruptions that alter the normal foveal anatomy and lead to severe, unilateral visual distortion. Surgical repair of IMHs often involves peeling the internal limiting membrane (ILM) or
injecting ocriplasmin into the vitreous cavity to help close the retinal hole. 32,33 Another pathology that often serves as our control is a visually significant epiretinal membrane (ERM), which is a thin fibrocellular membrane that forms over the vitreoretinal interface, causing disruption of the normal foveal contour and distorting vision. The exact mechanism for ERM formation is unknown; however, it is believed to be related to cellular changes induced by a posterior vitreous detachment (PVD). 34

Although these two conditions are noninflammatory, they likely alter the molecular composition of the vitreous. Likewise, key molecular alterations were detected by proteomic analysis of vitreous from patients undergoing IMH repair, likely representing an underlying pathogenesis driving the formation of macular holes. These include an increased expression of complement pathway effectors and α-2–macroglobulin, a major inducer of Müller cell migration. 32 Similarly, analysis of vitreous samples from patients undergoing surgical repair for an ERM identified increased levels of α1-antitrypsin, apolipoprotein-A1, and transthyretin compared to those from IMH vitreous samples. 34 As an alternative source of control samples, Wu et al. 35 argued that postmortem healthy eyes might be appropriate. 35 However, postmortem changes in the vitreous can be reflected in the proteome, confounding the results. 36,37 These data reveal how important considerations must be made by the researcher regarding control sample selection for proteomic studies.

Summary of Analytical Methods

Once surgical specimens are properly collected, processed, and stored, their proteomic composition can be analyzed. The choice of an analytical method depends largely on the question being asked. For example, in the case of characterizing an inflammatory disease, the clinician or researcher may wish to focus exclusively on identifying cytokine signaling proteins in a biological sample using multiplex immunoassays. Multiplex immunoassays are a powerful and efficient approach to simultaneously quantifying hundreds of proteins in a biological sample, reducing assay costs, time, and the sample volume required for analysis. 38

For idiopathic or poorly-characterized diseases, an unbiased approach, like shotgun mass spectrometry (MS), may be more appropriate. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a powerful analytical technique that ionizes molecular species and sorts ions based on their mass-to-charge ratio (m/z). This technique is used in a shotgun approach to catalog and quantify the thousands of proteins in a biological sample, which often is performed in tandem with liquid chromatography to separate peptides by size and hydrophobicity before they are ionized. Beforehand, samples are proteolytically digested with trypsin (or another protease) to generate a peptide mixture with less biochemical heterogeneity and simplify the process of protein separation, ionization, and MS characterization. 39

Before LC-MS/MS analysis, peptides may be fractionated by strong-cation exchange chromatography (SCX) or isoelectric focusing (IEF). 39 However, advances in liquid chromatography, namely ultrahigh-pressure liquid chromatography (UPLC), reduce the need to fractionate peptides beforehand. 40

Once separated and before entering the mass spectrometer, aqueous phase analytes are ionized to form gas-phase ions. Although many methods exist for this step, biological MS generally uses soft ionization techniques (like electrospray ionization [ESI] and matrix-assisted laser desorption ionization [MALDI]) because they leave large molecules intact. 40 Gas-phase ions then are directed toward the mass analyzer, where they are isolated by time (time-of-flight devices; TOF) or space (trap devices) before hitting the detector. 39 In the mass spectrometer, isolated peptides produce a fragmentation pattern that yields an individual mass spectrum. Highly advanced bioinformatics algorithms exist that match the thousands of spectra obtained from an LC-MS/MS experiment to known sequences of proteins within large spectral libraries. 41–44 One limitation to this approach is that it can only compare sample peptides to those that were previously identified, so advances in search algorithms incorporate simulated proteome-wide spectral libraries, to increase assignments of unique and novel peptides. 45

Once peptides are identified, they are quantified using unlabeled and labeled methods. Unlabeled methods include spectral counting or data-independent acquisition (DIA). In DIA MS, peptides within defined m/z windows are fragmented and analyzed without relying on predefined peptides of interest. 46 Labeled methods include isotope-coded affinity tags (ICAT), isobaric tags for relative and absolute quantification (iTRAQ), and multiple reaction monitoring (MRM). 40 Also referred to as selective reaction monitoring (SRM), MRM is a MS method that detects and quantifies selected target peptides from a complex mixture of proteins. 47 Prespecified
peptide-precursor ions and their fragments allow for highly-sensitive, reproducible quantification of targeted proteins. This method has advantages over multiplex ELISAs, since it does not rely on antibody quality, and can detect posttranslational modifications (PTMs) and short nucleotide modifications (SNPs) that would otherwise be missed by ELISA (Table 1).47

Vitreous and aqueous, like many serum samples, contain abundant levels of albumin and immunoglobulins19,48 so these proteins often are depleted before MS analysis so that less abundant proteins can be detected and quantified.49 This process can create false-negative results, however, since many proteins bind to albumin and, therefore, may be depleted during preprocessing.19 Another valuable component of these biopsy fluids is their exosome content. Exosomes are endosome-derived microvesicles released from cells that contain intracellular and membrane-bound proteins, DNA, and RNA.50 Exosomes frequently are isolated from biopsy fluids (e.g., plasma, cerebrospinal fluid [CSF], urine, saliva, synovial fluid, and so forth) and are reported to regulate cellular processes, such as apoptosis, angiogenesis, and inflammation.50–54 Fractionation of liquid biopsy fluids allows for exosome isolation and proteomic detection of their contents.51 Previous studies have identified exosomes in human aqueous humor as well as in the vitreous of uveal melanoma and ERM/IMH patients.55–57 Proteomic analysis of vitreous and aqueous exosomes can expand knowledge of retinal disease pathophysiology and identify novel disease biomarkers. As MS technology advances, sample preprocessing and fractionation may be minimized for proteomic analysis, thereby reducing the number of false-negatives and improving the time from sample collection to analysis.40 Figure 2 summarizes the personalized proteomics pipeline for ophthalmic tissues.

Challenges nevertheless remain when it comes to downstream analysis and management of large LC-MS/MS datasets. Shotgun proteomic experiments can produce data on thousands of proteins, for which meaningful interpretation requires advanced bioinformatics and statistical expertise. Once MS spectra are matched to their respective proteins and quantified, researchers can perform gene ontology as well as pathway and network analysis to interpret the data in a biological or clinical context. This may provide insight into how molecular pathways are affected in diseased tissues. From these data, researchers can study the relevant proteins, their functions, and how they relate to disease onset, timing, severity, and response to therapy. Table 2 summarizes software tools commonly used for bioinformatics analysis of proteomics data. Certain analyses (e.g., Venn diagram, gene ontology, and network analysis) do not incorporate quantitative data (e.g., spectral count or ion abundance), so critical information often is lost. To preserve these important data, we recently developed ProSave, a Java-based program that retrieves quantitative data (e.g., ion abundance or spectral counts) from a curated list of proteins in large proteomics datasets so researchers can derive a better understanding of each protein in a proteomics dataset. For proteomic analysis, development of standardized and user-friendly bioinformatics pipelines will streamline application to routine clinical practice.

Patient Stratification—Proteomics for Biomarker Identification

The proteome represents a network of end products generated from a series of processes related to protein synthesis within a specific cellular environment.58 Biomarkers, on the other hand, are defined by the Biomarkers Definitions Working Group as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”59 Several intra- and extracellular factors influence the cellular protein profile: (1) early on by the DNA sequence; (2) intermediately by translational, posttranslational, and regulatory steps; and (3) ultimately by the degradative stimuli.58 Thus, proteomic profiles might represent the ultimate biomarkers of cellular status in health and disease.

The discovery of proteomic biomarkers already has improved our understanding of the molecular mechanisms of diseases and should soon become a helpful diagnostic and risk-stratification tool, allowing individualized treatment for safer and more effective therapies. Disease processes alter cellular function and gene expression, such that changes in the protein profile can be used for diagnosis and prognosis.40,60 Normal aqueous humor and vitreous contain endogenously produced proteins that ocular diseases may alter.16,23 Thus, for many eye diseases, the aqueous humor and vitreous may potentially represent readily accessible repositories of proteomic biomarkers.16,61 Unbiased and untargeted proteomic approaches, such as LC-MS/MS, are ideal for
Table 2. Bioinformatics Resources for Personalized Proteomics

<table>
<thead>
<tr>
<th>Computational Tool</th>
<th>Description</th>
<th>Website</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytoscape</td>
<td>Network visualization and manipulation</td>
<td><a href="http://www.cytoscape.org/">http://www.cytoscape.org/</a></td>
<td>Shannon et al.⁹⁸</td>
</tr>
<tr>
<td>PANTHER</td>
<td>Gene ontology</td>
<td><a href="http://pantherdb.org/">http://pantherdb.org/</a></td>
<td>Thomas et al.¹⁰⁰</td>
</tr>
<tr>
<td>ProSave</td>
<td>Data management and comparative analysis</td>
<td><a href="https://github.com/MahajanLab/ProSave">https://github.com/MahajanLab/ProSave</a></td>
<td>Machlab et al.¹⁰¹</td>
</tr>
<tr>
<td>STRING</td>
<td>Network analysis</td>
<td><a href="https://string-db.org/cgi/input.pl">https://string-db.org/cgi/input.pl</a></td>
<td>Szklarczyk et al.¹⁰²</td>
</tr>
<tr>
<td>WebGestalt</td>
<td>Pathway analysis</td>
<td><a href="http://www.webgestalt.org/option.php">http://www.webgestalt.org/option.php</a></td>
<td>Wang et al.¹⁰³</td>
</tr>
</tbody>
</table>

Figure 2. Personalized proteomics pipeline for precision health in ophthalmology: liquid vitreous biopsies can be obtained in the operating room using a vitreous cutter or 23-gauge needle (left). Vitreous samples can be analyzed for protein content using multiplex ELISA arrays (top row). Custom or commercial antibody arrays quantify protein levels in biological samples using fluorescence or chemiluminescence means. Alternatively, vitreous fluid can be analyzed using a mass spectrometry approach (bottom row). Protein mixtures are digested with trypsin (or another digestive protease) and peptides are extracted with organic solvents. Analytes can be enriched using a variety of affinity chromatography techniques. Chromatography (HPLC, UPLC) is used to separate peptides before ionization and mass acquisition by mass spectrometry (e.g., ESI-MS/MS and MALDI-TOF MS/MS). Highly-advanced algorithms (e.g., MASCOT, OMSSA, and X!Tandem) match the thousands of spectra to known protein sequences and proteins quantified either through unlabeled (e.g., spectral counting or DIA) or labeled methods (e.g., MRM/SRM and iTRAQ). Once protein levels are quantified (either from an ELISA or MS experiment), downstream bioinformatics analysis (right) can help put the identified proteins into the context of the disease.
identifying biomarkers in aqueous or vitreous biopsies. Even without a priori knowledge of a disease or its causative agent, one can identify novel biomarkers. Such an approach can aid in the systematic understanding of pathophysiology, simply by cataloging upregulated and downregulated proteins in a tissue sample.

Current ophthalmic proteomic studies are investigating the protein profiles related to age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal detachment (RD), proliferative vitreoretinopathy (PVR), uveitis, and ocular cancers.15,61,62 Past proteomic studies from liquid biopsies of patients with vitreoretinal diseases are summarized in Table 3. The methods used in those studies ranged from multiplex ELISA arrays to shotgun MS analysis. For each of the pathologies analyzed, several proteins were found to be up- and downregulated, but further studies are needed to determine how to use this information in clinical practice.

**Proteomics for the Diagnosis of Idiopathic Uveitis**

Uveitis is a family of ocular inflammatory diseases that may involve the iris, ciliary body, vitreous and/or choroid, and it illustrates the potential that personalized proteomics may have to aid in diagnosis. Although often restricted to the eye, uveitis can be an early symptom of debilitating systemic disease with a prevalence of 1 in 4500 people63–67 and should be treated aggressively to prevent significant visual morbidity and blindness. Prior to diagnosis, posterior uveitis affects the choroid and retina, encompassing a group of inflammatory diseases that account for approximately 10% of preventable blindness in the United States.68 This can be caused by infectious agents or systemic inflammatory disease and has high morbidity because the retina is intolerant of immunologic insult. Despite advances in diagnostic procedures, the etiology for over 50% of posterior uveitis cases is not known and, thus, they are labeled as “idiopathic.”68 In certain cases, such as acute retinal necrosis due to a member of the herpes virus family, the inciting agent can be treated directly.69 In most cases, however, the etiologic agent is unknown, and therapy is broadly directed at the inflammatory mediators that cause damage to ocular tissues. Corticosteroids have been the mainstay of uveitis treatment since their introduction in the 1950s, but long-term use results in unfavorable systemic side effects and vision-threaten-
<table>
<thead>
<tr>
<th>Disease(s)</th>
<th>Tissue</th>
<th>Detection Platform</th>
<th>Biomarkers</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERM</td>
<td>Vitreous</td>
<td>Electrophoresis, MS</td>
<td>SERPINA1, APOA1, TTR</td>
<td>Mandal et al.34</td>
</tr>
<tr>
<td>IMH</td>
<td>Vitreous</td>
<td>LC-MS/MS</td>
<td>A2M, C3, C4A, CFB, CFH</td>
<td>Zhang et al.32</td>
</tr>
<tr>
<td>nvAMD</td>
<td>Vitreous</td>
<td>Electrophoresis, LC-MS/MS, ELISA</td>
<td>SERPINA1, APOA1, RBP3, TF, TTR</td>
<td>Koss et al.104</td>
</tr>
<tr>
<td>nvAMD</td>
<td>Vitreous</td>
<td>Electrophoresis, LC-MS/MS, ELISA</td>
<td>CLU, OPTC, PEDF, PTGDS</td>
<td>Nobl et al.105</td>
</tr>
<tr>
<td>nvAMD</td>
<td>Aqueous</td>
<td>Electrophoresis, LC-MS/MS, ELISA</td>
<td>LCN1, CRYAA</td>
<td>Yao et al.26</td>
</tr>
<tr>
<td>nvAMD</td>
<td>Aqueous</td>
<td>LC-MS/MS</td>
<td>CTSD and KRT8</td>
<td>Kang et al.55</td>
</tr>
<tr>
<td>nvAMD</td>
<td>Aqueous</td>
<td>MRM-MS</td>
<td>CEP55, ACT, DSG1, SOD3, FLG2, 26S proteasome, SERPINA5, C3, PKP2, LRRRC15.</td>
<td>Kim et al.25</td>
</tr>
<tr>
<td>AMD</td>
<td>Aqueous</td>
<td>LC-MRM-MS</td>
<td>CTSD, KRT8, KRT14, MYO9, HSP70, ACTA</td>
<td>Kang et al.55</td>
</tr>
<tr>
<td>AMD</td>
<td>Exosomes</td>
<td>LC-MS/MS</td>
<td>OPTC, CRYBB2, CRYAB</td>
<td>Patel et al.106</td>
</tr>
<tr>
<td>X-linked Retinoschisis</td>
<td>Schisis Fluid</td>
<td>Electrophoresis, MS</td>
<td>RDH14, SGCE, STK26, TENM1, ALMS1, ZFP90, GRIN1, QSER1, ESCO1, KIF4A, CAPN1,</td>
<td>Sudha et al.107</td>
</tr>
<tr>
<td>ROP</td>
<td>Vitreous</td>
<td>Electrophoresis, LC-MS/MS</td>
<td>RBP3, TF, ALB, PEDF, HPDS, TTR, A2M, CP, AFP, A1BG, HPX.</td>
<td>Sugioka et al.108</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>Tumor</td>
<td>DIGE, LC-MS/MS</td>
<td>FGB, CFH, FN1, ITIH4, FGG, HP, IGHA1, AFM, IGHM, LUM, SERPINA7, VTN.</td>
<td>Naru et al.109</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>Vitreous</td>
<td>iTRAQ, LC-MS/MS</td>
<td>GFAP, CRABP1, MMP2, and TNC</td>
<td>Naru et al.110</td>
</tr>
<tr>
<td>Coat's Disease DR</td>
<td>Aqueous</td>
<td>iTRAQ, LC-MS/MS</td>
<td>HP and APOC-I</td>
<td>Yang et al.111</td>
</tr>
<tr>
<td>DR</td>
<td>Vitreous</td>
<td>Electrophoresis, MS</td>
<td>PEDF, SERPINA1, AHSG, and C4</td>
<td>Nakanishi et al.27</td>
</tr>
<tr>
<td>PDR</td>
<td>Vitreous</td>
<td>Electrophoresis, MS</td>
<td>TF, SERPINC1, SERPINA3, AHSG, HPX, SERPINA1, APOA1, APOJ, FGG, and HP</td>
<td>Yamane et al.112</td>
</tr>
<tr>
<td>PDR</td>
<td>Vitreous</td>
<td>Electrophoresis, MS</td>
<td>PEDF, SERPINA5, APOA-IV, PTGDS, SERPINA1, ANKRD15, AHSG, and SPTBN5</td>
<td>Kim et al.113</td>
</tr>
<tr>
<td>PDR</td>
<td>Vitreous</td>
<td>DIGE</td>
<td>ZAG, APOA1, APOH, FGA, C3, C4b, C9, and CFB</td>
<td>Garcia-Ramirez et al.114</td>
</tr>
<tr>
<td>PDR</td>
<td>Vitreous</td>
<td>Electrophoresis, LC-MS/MS</td>
<td>AGT, C3, CFI, F2, SERPINA1, and SERPINC1</td>
<td>Gao et al.115</td>
</tr>
</tbody>
</table>
platforms, such as multiplex ELISA arrays or LC-MS/MS, have the potential to differentiate many etiologies of inflammatory eye diseases that otherwise are difficult to diagnose. In a previous study by our group, vitreous biopsies from 15 uveitis patients (three with idiopathic posterior uveitis, four with viral endophthalmitis, one with multifocal choroiditis, one with neovascular inflammatory vitreoretinopathy, two with autoimmune retinopathy, and one with HLA-B27 uveitis) were analyzed by a cytokine array that simultaneously measured the levels of 200 cytokines. Differential expression analysis and hierarchical heatmap clustering detected similarities and differences in the cytokine profiles and identified a cytokine signature common to these forms of uveitis (IL-23, PDGFRb, SCF, TIMP-1, TIMP-2, BMP-4, NGF, IGFBP-2, IL-17R, and IL-1RI; Table 3). These data suggest that seemingly different diseases might be targetable and treated by the same therapies. More importantly, this could redirect the diagnosis and treatment of a patient who had been previously diagnosed with idiopathic posterior uveitis. In a similar study, Kuiper et al. used a multiplex ELISA (25 proteins) to analyze 175 aqueous humor samples.

<table>
<thead>
<tr>
<th>Disease(s)</th>
<th>Tissue</th>
<th>Detection Platform</th>
<th>Biomarkers</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDR</td>
<td>ERM</td>
<td>LC-MS/MS</td>
<td>POSTN</td>
<td>Takada et al.116</td>
</tr>
<tr>
<td>DR</td>
<td>Aqueous</td>
<td>Electrophoresis, MS</td>
<td>APOA1, TF, KRT9, KRT10, PODN, MMP12, GRB10, BAIAP2, SEPP1, CBS, RGAG1</td>
<td>Chiang et al.28</td>
</tr>
<tr>
<td>DR and PDR</td>
<td>Tears</td>
<td>iTRAQ, LC-MS/MS</td>
<td>LCN1, LTF, LACRT, LYZ, and SCGB1D1</td>
<td>Csosz et al.117</td>
</tr>
<tr>
<td>RRD, Elevated IOP</td>
<td>Aqueous</td>
<td>LC-MS/MS</td>
<td>CYTC, HEPC</td>
<td>Velez et al.118</td>
</tr>
<tr>
<td>RRD, DR, PDR, PVR</td>
<td>Vitreous</td>
<td>Electrophoresis, MS</td>
<td>AAT, APOA4, ALB, and TF</td>
<td>Shitama et al.119</td>
</tr>
<tr>
<td>RRD, PDR, PVR, MHRD</td>
<td>Silicon Oil</td>
<td>Multiplex ELISA</td>
<td>FGF2, IL-10, IL-12p40, IL-8, VEGF, and TGF</td>
<td>Kaneko et al.120</td>
</tr>
<tr>
<td>RRD, AMD, PVRL, INIU</td>
<td>Aqueous</td>
<td>Multiplex ELISA</td>
<td>IL-10, IL-21, and ACE</td>
<td>Kuiper et al.85</td>
</tr>
<tr>
<td>RRD and PVR</td>
<td>Vitreous</td>
<td>Electrophoresis, LC-MS/MS</td>
<td>Coagulation cascade proteins, EF21, and p53</td>
<td>Yu et al.121</td>
</tr>
<tr>
<td>PVR</td>
<td>Vitreous</td>
<td>Multiplex ELISA</td>
<td>mTOR signaling effectors</td>
<td>Roybal et al.87</td>
</tr>
<tr>
<td>PVR</td>
<td>Vitreous</td>
<td>LC-MS/MS</td>
<td>Kininogen 1</td>
<td>Yu et al.122</td>
</tr>
<tr>
<td>Idiopathic ERM</td>
<td>Aqueous, Vitreous</td>
<td>iTRAQ, LC-MS/MS</td>
<td>KNG1, FGA, CTSD, CPE, FSTL1, CDHR1, DKK3, B3GNT1, LYPD3, EON1, MIF, and</td>
<td>Pollreisz et al.123</td>
</tr>
<tr>
<td>RVO</td>
<td>Vitreous</td>
<td>LC-MS/MS</td>
<td>CLU, C3, IGLL5, OPTC and VTN</td>
<td>Reich et al.124</td>
</tr>
<tr>
<td>BRVO</td>
<td>Vitreous</td>
<td>LC-MS/MS</td>
<td>CLU, C3, PTGDS, and VTN</td>
<td>Dacheva et al.125</td>
</tr>
<tr>
<td>Posterior Uveitis</td>
<td>Vitreous</td>
<td>Multiplex ELISA</td>
<td>IL-23, PDGFRb, SCF, TIMP-1, TIMP-2, BMP-4, NGF, IGFBP-2, IL-17R, and IL-1RI</td>
<td>Velez et al.15</td>
</tr>
<tr>
<td>Anterior Uveitis - JIA</td>
<td>Aqueous, Vitreous</td>
<td>LC-MS/MS</td>
<td>TTR, VEGF, IL-6, mTOR signaling effectors</td>
<td>Kalinina et al.126</td>
</tr>
<tr>
<td>ADNIV</td>
<td>Vitreous</td>
<td>Multiplex ELISA</td>
<td></td>
<td>Velez et al.89</td>
</tr>
</tbody>
</table>

nvAMD, neovascular AMD; ROP, retinopathy of prematurity; PDR, proliferative diabetic retinopathy; IOP, intraocular pressure; RRD, rhegmatogenous retinal detachment; MHRD, macular hole-related retinal detachment; PVRL, primary vitreoretinal lymphoma; INIU, idiopathic noninfectious uveitis; RVO, retinal vein occlusion; BRVO, branch retinal vein occlusion.

Table 3. Continued
from four retinal diseases (rhegmatogenous RD, AMD, primary vitreoretinal lymphoma, and idio-pathic noninfectious uveitis). Three proteins (IL-10, IL-21, and ACE) were further analyzed, using a parsimonious model that could distinguish the four diseases from each other, with 86.7% accuracy. This study highlights the potential for proteomic analysis to guide the definitive diagnosis of vitreoretinal diseases.

**Proteomics for Drug Repositioning**

Drug repositioning is defined as applying approved drugs and compounds towards new indications, which often are rare diseases with few therapeutic options. Ophthalmology is rife with “orphan” diseases (e.g., inherited retinal degenerations and chronic inflammatory diseases) that have small market capitalization, which often present a financial barrier for therapeutic development. The research and development of new drugs often is capital- and time-intensive. When a compound may show therapeutic promise, it may cost upwards of a billion dollars and a further decade of basic research and clinical trials to further develop it into an approved and marketable therapy. Drug repositioning offers a route for clinicians and researchers to circumvent this complex pipeline by using drugs that have standardized, therapeutic doses and well-characterized side-effect profiles.

To identify candidate drugs for repositioning, many current prediction methods make use of genomics-based analyses and retrospective computational methods. For directing treatment of vitreous diseases, personalized proteomics may have more value than personalized genomics because it places more emphasis on biomarkers with therapeutic potential. Using this method, molecular constituents of diseased tissues (e.g., vitreous or aqueous) can be identified and measured. Then, elevated molecular disease effectors can be targeted. Such an approach may be most beneficial in vitreoretinal diseases where nonspecific immunosuppressive medications are the first-line treatments.

PVR is a vision-threatening complication of RD repair characterized by the formation of fibrotic membranes that reopen previously repaired retinal tears and initiate new ones. Its treatment often requires delicate and complex surgery to remove fibrotic membranes, often with poor visual outcomes. These patients face numerous clinical risk factors, such as prior PVR, longer lasting RD, vitreous or choroidal hemorrhage, and poorer initial visual acuity. Despite this, identification of clinical risk factors does little to improve PVR therapy. Corticosteroids and immunosuppressive medications (e.g., 5-fluorourail [5-FU] and daunorubicin) are the mainstay of pharmacologic PVR treatment, but often are ineffective.

In the case of proteomic analysis, if molecular risk factors can be identified, then they might point to more robust biomarkers and drug targets for precise, patient-specific treatment. Proteomic analysis of vitreous biopsies from patients with early and advanced PVR (grades A-B and C, respectively) suggested key differences in the cellular and molecular profile of the two disease stages: early PVR was characterized by T-cell recruitment and mTOR signaling, whereas the cytokine signatures in the advanced PVR proteome suggested monocyte recruitment. This finding strongly suggests that mTOR inhibitors, like intravitreal Sirolimus, would be beneficial in treating PVR. Pathway analysis of differentially expressed proteins in PVR vitreous also suggested why PVR patients may be nonresponsive to glucocorticoids: PVR vitreous contains elevated levels of IL-13, a cytokine shown to make monocytes resistant to glucocorticoids and reduce their suppressive effects on IL-6 production.

The ability of proteomics to guide drug repositioning is exemplified in a prior study by our group, where proteomic analysis of vitreous biopsies successfully directed the repositioning of available drugs for Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV; OMIM 193235) patients. ADNIV is a rare, progressive inflammatory intraocular disease caused by mutations in the CAPN5 gene. Before culminating in blindness, ADNIV disease progresses in a series of pathologic stages, characterized by synaptic signaling defects, inflammatory cell infiltration, neovascularization, and intraocular fibrosis. Before our study, ADNIV patients were treated with nonspecific immunosuppressive medications, such as oral corticosteroids and infliximab (anti-TNF-α). Our proteomic analysis of ADNIV vitreous revealed that TNF-α levels were normal, explaining why infliximab therapy failed in these patients. The analysis further revealed that the ADNIV vitreous contained abundant levels of VEGF, T-cell proliferative markers, and IL-6. Based on these proteomic data we repositioned bevacizumab (anti-VEGF monoclonal antibody), intravitreal methotrexate (T-cell inhibitor), and tocilizumab (anti-IL-6 monoclonal antibody) and successfully mitigated neovascularization, inflammatory cell infiltration, and persistent fibrosis in these patients. Similar
strategies can be applied to other diseases where liquid biopsies can be collected to select drug targets and streamline trials.

Future Directions

Historically, physicians have had to use patients’ physical signs and symptoms in a constant race to cure poorly-understood diseases. The resulting standardized treatments, often driven by trial and error, cost patients physically and financially. Recent advances in genetics, proteomics, and other molecular sciences are changing the playing field, putting healthcare providers in the lead by allowing them to cure diseases in their earliest stages or even catch them before they appear. Precision Health makes use of big data sets and advanced bioinformatics pipelines to analyze molecular and clinical information to customize patient care. The collaboration between basic scientists, engineers, entrepreneurs, health care providers, and patients is unlocking the causes and prevention of diseases and bringing innovative treatments to the bedside. Molecular diagnoses and targeted treatments hold the key to personalized health that will enable us to live better, longer lives. The significant role Precision Health has had in transforming cancer treatments has inspired changes across the medical fields, including ophthalmology, where ophthalmologists and bench scientists are on the cusp of unraveling the molecular and genetic makeup of blinding eye diseases, moving them away from symptom-based treatment plans to a precision-health approach.

Personalized proteomics offers many advantages over alternative precision-health platforms for the diagnosis and treatment of vitreoretinal diseases. For example, in clinical practice, a patient’s genetic profile only denotes risk, which often does little to improve their treatment in the near term. Further, gene expression levels often do not correlate well with protein levels and turnover. In contrast, LC-MS/MS analysis can provide information on changes in protein expression levels, posttranslational modifications, metabolites, and response to therapy—information that cannot be ascertained using genomics-based methods (Table 1). Proteomic analysis of vitreous biopsies allows identification of molecular constituents in the diseased tissue that can be targeted by available drugs. Approved drugs can be repositioned in real-time to provide precise, personalized therapy. Also, proteomic analysis can point out which drugs to avoid. In the case of ADNIV, when it became apparent that the patient’s vitreous contained normal levels of TNF-α, a needless infliximab therapy was halted. Similarly, our previous proteomic studies on PVR detected vitreous cytokines that could explain why corticosteroids were ineffective in the advanced, fibrotic stage of the disease. Since the retina secretes proteins into the vitreous, proteomic biomarkers may be a more rapid way to monitor therapeutic responses or the success of gene therapy trials than clinical outcomes.

Proteomic analysis is already being applied successfully to other diseases, such as chronic kidney disease (CKD). An MS-based approach used by Good et al. analyzed a panel of 273 urinary proteins (named the CKD273 panel) to screen normo-albuminemic patients at risk for progression to CKD. This panel was validated in several studies in patients with earlier-stage disease, and in larger cohorts, including patients with diabetic kidney disease. This led to the design of the first urinary proteomics-guided intervention trial, PRIORITY (NCT02040441), in which CKD237-positive patients were randomized to receive spironolactone or placebo. The success of this trial led to the support of CKD237 by the Food and Drug Administration (FDA). The success of the PRIORITY trial for CKD highlights the need for prospective validation of candidate proteomic biomarkers in larger patient cohorts. Biomarkers that repeatedly appear in multiple studies and populations are more convincing and, thus, more likely to be reliable indicators of disease risk, progression, and response to therapy. Validated biomarkers can then be used in a more routine fashion in the clinical setting. Although numerous proteomic studies identified biomarkers and drug targets for vitreoretinal diseases (Table 3), further analysis and validation is required to determine their role in disease, reproducibility, sensitivity, and specificity.

Finally, although we focused on the vitreous in this review, other ophthalmic tissues can be sampled routinely for proteomic analysis in the clinical setting. Tear fluid, for example, contains complex mixtures of proteins, lipids, and metabolites secreted from the lacrimal gland, cornea, and vascular sources. Absorbent materials (e.g., Schirmer’s strips) and microcapillary tubes can be used to sample tear fluid noninvasively (5–10 μL on average) from patients. Despite the small sample volume, proteomic analysis has identified close to 2000 unique proteins in human tear fluid and numerous studies identified biomarkers for ocular surface and lacrimal gland diseases. We anticipate that advances in small-volume proteomics and safe surgical acquisition of ocular fluids from
different anatomical sites will give new insight into the pathophysiology and treatment of eye disease.

**Acknowledgments**

The authors thank Alton Szeto for anatomic illustrations. Permission to publish was granted by the original artist.

Supported by National Institutes of Health (NIH; Bethesda, MD) Grants R01EY026682, R01EY024665, R01EY025225, R01EY024698, and R21AG050437 (VBM and AGB) and Research to Prevent Blindness (RPB), New York, NY (VBM and AGB), and NIH Grants F30EYE027986 and T32GM007337 (GV). The Barbara & Donald Jonas Laboratory of Regenerative Medicine and Bernard and the Shirlee Brown Glaucoma Laboratory are supported by the NIH Grants 5P30EY019007, R01EY018213, R01EY024698, and R21AG050437, National Cancer Institute Core Grant 5P30CA13696, the RPB Physician-Scientist Award, and unrestricted funds from the RPB. SHT is a member of the RD-CURE Consortium and is supported by the Tistou and Charlotte Kerstan Foundation, the Schneeweiss Stem Cell Fund, New York State (C029572) the Joel Hoffman Fund, the Professor Gertrude Rothschild Stem Cell Foundation, and the Gebroe Family Foundation. The authors alone are responsible for the content and writing of this paper.

Author Contributions: VBM had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drafting of the manuscript: GV, PHT, TC, GYC, DAM, SHT, AGB, VBM. Critical revision of the manuscript for important intellectual content: SHT, AGB, VBM. Obtained funding: VBM. Administrative, technical, and material support: VBM. Study supervision: VBM.

Disclosure: G. Velez, None; P.H. Tang, None; T. Cabral, None; G.Y. Cho, None; D.A. Machlab, None; S.H. Tsang, None; A.G. Bassuk, None; V.B. Mahajan, None

**References**


68. Lee K, Baijwa A, Freitas-Neto CA, Metzinger JL, Wentworth BA, Foster CS. A comprehensive review and update on the non-biologic
Velez et al.


101. Machlab DA, Velez G, Bassuk AG, Mahajan VB. ProSave: an application for restoring quantitative data to manipulated subsets of proteins [software], 2018. Available at: https://github.com/MahajanLab/ProSave


118. Velez G, Roybal CN, Binkley E, Bassuk AG, Tsang SH, Mahajan VB. Proteomic Analysis of Elevated Intraocular Pressure with Retinal


